We are live on ! Find out more
ANAB icon

AnaptysBio

114 hedge funds and large institutions have $831M invested in AnaptysBio in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 36 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

36,524% more call options, than puts

Call options by funds: $6.23M | Put options by funds: $17K

31% more capital invested

Capital invested by funds: $633M → $831M (+$198M)

4.74% more ownership

Funds ownership: 110.55%115.29% (+4.7%)

6% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 36

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

8% less funds holding

Funds holding: 124114 (-10)

48% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 21

Holders
114
Holders Change
-10
Holders Change %
-8.06%
% of All Funds
1.96%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
11
Increased
38
Reduced
36
Closed
21
Calls
$6.23M
Puts
$17K
Net Calls
+$6.21M
Net Calls Change
+$1.38M

ANAB Hedge Fund Activity: Q3 2022 in Review

114 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q3 2022, worth a combined $831M — up 31% from $633M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of ANAB and 11 opened new positions — a net loss of 10 holders — while 36 trimmed existing stakes and 38 added.

The largest buyer was Point72 Asset Management, adding an estimated $39.2M. The largest seller was Soleus Capital Management, cutting an estimated $13.6M.

  • 114 institutional investors held AnaptysBio (ANAB) as of Q3 2022, down from 124 in Q2 2022.
  • Funds reported $831M of AnaptysBio stock for Q3 2022, up 31% quarter-over-quarter.
  • 11 funds opened new AnaptysBio positions in Q3 2022 and 21 closed out, a net change of -10 holders.
  • The largest AnaptysBio buyer in Q3 2022 was Point72 Asset Management, an estimated $39.2M added.
  • The largest AnaptysBio seller in Q3 2022 was Soleus Capital Management, an estimated $13.6M sold.

Based on aggregated 13F filings for Q3 2022.